Ingevity raises full-year 2026 net sales outlook to $1.05 bln-$1.15 bln
Company sees 2026 adjusted EBITDA between $380 mln and $400 mln
Ingevity expects 2026 diluted adjusted EPS of $5.00-$5.45
Overview
US specialty materials firm's Q2 adjusted EPS from continuing operations beat analyst expectations
Q2 net sales fell 5% yr/yr, mainly due to Road Markings divestiture
Company completed sale of Road Markings product line and raised full-year adjusted EBITDA outlook
Result Drivers
Road Markings divestiture - Net sales fell 5% yr/yr, mainly due to the sale of the Road Markings product line in April
Segment growth - Excluding Road Markings, sales rose 5% with growth across all three segments, driven by higher volumes, favorable mix, and pricing actions
Advanced polymer technologies - Segment benefited from higher prices, favorable mix toward higher-value products, and competitor supply disruptions
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the diversified chemicals peer group is "buy"
Wall Street's median 12-month price target for Ingevity Corp is $90.00, about 27.4% above its July 29 closing price of $70.62
The stock recently traded at 13 times the next 12-month earnings vs. a P/E of 14 three months ago
NGVT•
